Methods and compositions for treating triple negative breast cancer (tnbc)

Inventors analyzed the prognostic value of tumor and stromal-derived SPARC in a large series that included 148 non-metastatic TNBC patients with a long follow-up by immunohistochemistry. They show that SPARC expression was detected in cancer cells (42.4%), cancer-associated fibroblasts (CAFs) (88.1%), TAMs (77.1%), endothelial cells (75.2%) and TILs (9.8%). Recurrence-free survival (RFS) was significantly lower for patients with a positive expression of SPARC in CAFs (SPARC+ CAFs) with a median follow-up of 5.4 years. SPARC expression in CAFs was found to be an independent prognostic factor in multivariate analysis. Accordingly, the present invention relates to a method for predicting the survival time of a subject suffering from triple-negative breast cancer (TNBC) comprising determining the expression level of Secreted Protein Acidic and Rich in Cysteine (SPARC) in cancer-associated fibroblasts (CAFs) in a biological sample obtained from the subject wherein said positive expression of SPARC in CAFs (SPARC+CAFs) correlates with a short survival time of the subject.

Keywords: triple negative breast cancer (TNBC), Prognosis, Treatment Response Prediction, SPARC
Patent Application number: EP21 306 545.1 on 03/11/21
PCT/EP2022/080508 on 02/11/2022
Int J Cancer 2023 Mar 15 Alcaraz et al SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity doi: 10.1002/ijc.34345. Epub 2022 Nov 30.

You might also be interested in


Inserm Transfert

Research tool licensing team